On this page
How should Fast Track status changes be documented?
Retrieve the exact request or designation letter and indication, then identify what changed in evidence or development plans. Distinguish withdrawal of a pending request, correspondence about an existing designation and FDA’s disposition. Explain the factual implications and affected rolling-review arrangements while keeping the IND and other indications’ statuses separate.
Before you begin
Correspondence about an existing or requested Fast Track designation and related rolling-review arrangements. IND withdrawal is a separate action.
What you will prepare: A factual, indication-specific request or response with current status and downstream implications documented.
Sections covered in this guide (2)
Identify what changed and which status is affected
Retrieve the designation request, FDA designation letter, relevant indication and any rolling-review agreement. The guidance Appendix 1.A.5 explains that eligibility can be reconsidered as evidence and available therapies change. Distinguish sponsor withdrawal of a request/designation, an FDA proposal to rescind, and correspondence updating the evidence.
A negative study, new available therapy or changed development population needs a factual assessment. None should be hidden by writing a generic “program update.” Conversely, a new competing product does not by itself prove the designated drug no longer addresses unmet need; assess the actual evidence and agency position.
Make the requested disposition explicit
For 1.7.2, identify the product, IND, designated indication, relevant FDA letter and the exact request to withdraw the designation or pending request. State the supported reason and distinguish the status of the IND and other indications. For 1.7.4, identify the correspondence being answered, present new facts and explain their implications for the original rationale.
Where a rolling-review plan exists, identify affected portions and dates and request the necessary clarification of next steps. Do not assume withdrawal of Fast Track also withdraws the IND, marketing application or previously submitted reports. Preserve FDA’s response as the status record.
Worked check: one indication changes, another continues
Fictional exercise: development stops in one designated indication, but the product continues in a different indication. A draft saying “withdraw the product” obscures the decision. Name the exact designation and indication and state the separate development context without claiming new eligibility for the continuing indication.
If no designation letter can be located, determine whether the team is withdrawing a pending request or an actual designation. Leave status undetermined until that evidence is found.
Compare the original rationale with the changed facts
Appendix 1.A.5 of the expedited-program guidance addresses continued Fast Track designation. Use a comparison record to explain the change; the table is an internal drafting aid, not a formula that decides eligibility.
| Review item | Earlier basis | Current evidence or decision |
|---|---|---|
| Designated use | Exact indication in the FDA letter | Same use, changed population or discontinued program |
| Unmet need | Gap and available-therapy context supporting the request | New therapy or updated evidence relevant to that gap |
| Product potential | Evidence supporting the anticipated benefit | New results, limitations and implications for the rationale |
| Development program | Work intended to test the potential | Studies continuing, changed or no longer pursued |
| Rolling-review dependency | Agreed portions and dates, if any | Affected commitments and questions for FDA |
New-therapy exercise: another product is approved in the broader disease population. Identify its approved use, relevance to the designated subset and the need it addresses before drawing a conclusion about continued eligibility. The event deserves assessment, but neither automatic loss nor automatic retention follows from a competitor announcement. Explain the evidence FDA needs to understand the remaining rationale.
Use precise disposition language. “We no longer intend to pursue development for [designated use]” reports a program decision; “FDA removed the designation” asserts an agency action and needs the corresponding record. If responding to agency correspondence, identify its date and questions, then answer the actual concerns rather than supplying an unrelated commercial update.
Close the record by reconciling FDA’s response, the designation tracker and any agreed submission schedule. An internal decision to stop one indication does not establish withdrawal of the IND or other applications. Route a genuine IND withdrawal separately, and revisit the rolling-review plan with FDA where its assumptions changed.
Your preparation checklist
0/3 checkedUse this to track your review in this visit. Checks are not saved and do not establish regulatory compliance.
Frequently asked questions
Does a new competing therapy automatically remove Fast Track designation?
No. The guidance identifies changing therapy and emerging evidence as possible reasons the original unmet-need rationale may no longer hold. Assess the actual indication, treatment context and evidence, and retain FDA’s disposition. A new approval is a fact to evaluate, not by itself proof that the designation ended.
Is withdrawing Fast Track designation the same as withdrawing the IND?
No. Designation concerns a particular product-development use, while IND withdrawal is a separate regulatory action. Specify what is being requested and preserve the status of related programs accurately. Do not describe the entire IND as withdrawn because the sponsor stopped pursuing a designated indication.
What if the team cannot find a Fast Track designation letter?
Establish whether there was a pending request, a grant or a later agency disposition before describing the action. An internal tracker or a submitted request does not prove designation. Retrieve the source record and leave the status unresolved until the evidence supports the wording of the correspondence.
Can the sponsor assume an existing rolling-review schedule continues unchanged?
Do not infer that from the old schedule. Identify the agreement, indication and portions affected by the changed facts, and discuss the necessary disposition with FDA. The expedited-program guidance describes written agency responses to changes in an agreement to accept application portions; preserve the actual response.
Sources and revisions
Requirements, source recommendations and editorial preparation advice have different roles. Review the scope and revision of the source you use.
Guidance
Expedited Programs for Serious Conditions: Drugs and Biologics ↗Final May 2014; Fast Track §§V, IX and Appendices 1–2. PDF reopened September 22, 2026; not used to freeze unrelated accelerated-approval policy.
Technical specification · placement only
FDA eCTD v4.0 comprehensive hierarchy ↗Version 2.2, February 2025. Section 1.7.2. A heading identifies placement, not mandatory applicability.